WO2009157010A1 - Système de distribution de médicament par voie intraveineuse - Google Patents

Système de distribution de médicament par voie intraveineuse Download PDF

Info

Publication number
WO2009157010A1
WO2009157010A1 PCT/IN2008/000754 IN2008000754W WO2009157010A1 WO 2009157010 A1 WO2009157010 A1 WO 2009157010A1 IN 2008000754 W IN2008000754 W IN 2008000754W WO 2009157010 A1 WO2009157010 A1 WO 2009157010A1
Authority
WO
WIPO (PCT)
Prior art keywords
sodium
drug delivery
delivery system
intravenous drug
paracetamol
Prior art date
Application number
PCT/IN2008/000754
Other languages
English (en)
Inventor
Hari Ram Goel
Original Assignee
Akums Drugs And Pharmaceuticals Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akums Drugs And Pharmaceuticals Limited filed Critical Akums Drugs And Pharmaceuticals Limited
Publication of WO2009157010A1 publication Critical patent/WO2009157010A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Definitions

  • Filed of invention is related to the drug delivery system. More particularly field is related to the pharamaceuical and diclofenac sodium forumaltion for the intravenous administration of a drug, Most particularly invention is related a pharmaceutical composition for intravenous administration containing paracetamol and diclofenac sodium in an aqueous base.
  • a route of administration is the path by which a drug, fluid, poison or other substance is brought into contact with the body.
  • a substance must be transported from the site of entry to the part, of the body where its action is desired to take place (even if this only means penetration through the into the skin).
  • using the body's transport mechanisms for this purpose can be far from trivial,
  • the pharmacokinetics properties of a drug that is, those related to processes of uptake, distribution, and elimination) are critically influenced by the route of administration.
  • Routes of administration can broadly be divided into;
  • intraarterial into an artery
  • vasoioditor drugs in the treatment of vasospam
  • therobylotic drugs for treatment of embolisim
  • intramuscular into muscle
  • vaccines e.g. many vaccines , antibiotics, and long- term psychoactive agents
  • intraosseous infusion (into the bone marrow) is, in effect, an indirect intravenous access because the bone marrow drains directly into the venous system. This route is occasionally used for drugs and fluids in emergency medicine and paediatrics when intravenous access is difficult.
  • intrathecal into the spinal canal
  • Paracetamol or acetaminophen is a widely-used analgesic and antipyretic, unlike aspirin it is not a very effective anti-inflammatory agent. It is well tolerated, lacks many of the side-effects of aspirin and is available over-the-counter so it is commonly used for the relief of fever headaches, and other minor aches and pains. Paracetamol is also useful in the management of more severe pain, where it allows lower dosages of additional non-steroidal anti-inflammatory drugs (NSAIDs) to be used, and thereby minimizing overall side-effects. It is also used in combination with opioid analgesics It is a major ingredient in numerous cold and flu medicationsintraperitoneai (infusion or injection into the peritoneum) e.g. peritoneal dialysis.
  • NSAIDs non-steroidal anti-inflammatory drugs
  • Diclofenac with various drug dose combinations is a non-steroidal antiinflammatory drug (NSAiD) taken ⁇ o reduce inflammation and as an analgesic reducing pain in conditions sucrvas arthritis or acute injury It can also be used to reduce menstrua!.
  • NSAiD non-steroidal antiinflammatory drug
  • the name is derived from its chemical name: 2-(2,6- dichloranilino) phenylacetic acid
  • Diclofenac may also be a unique member of the NSAIDs.There is some evidence that diclofenac inhibits the lipoxygenase pathways, thus reducing formation of the leukotrienes ⁇ also pro-inflammatory autacoids). There is also speculation that diclofenac may inhibit phospholipase A 2 as part of its mechanism of action. These additional actions may explain the high potency of diclofenac - it is the most potent NSAiD on a broa ⁇ basis.
  • composition for oral administration for the treatment of acute pain and inflammation comprises an inclusion complex of a non-steroidal anti-inflammatory drug or a pharmaceutically acceptable salt thereof and a cyclodextrin, and a physiologically acceptable alkali agent selected from the group consisting of alkali and alkaline earth metal carbonates, bicarbonates, phosphates and hydroxides, and water soluble amines, in an amount equivalent to between 2 and 30 molar equivalents inclusive of the non-steroidal anti-inflammatory drug, the alkali agent being capable of forming an alkaline diffusion layer around the composition in the grastrointestinal tract.
  • United States Patent 6,028,222 discloses a combination liquid paracetamol combination. Novel stable paracetamoi compositions for use in therapeutic chemistry and specifically galenic pharmacy are disclosed.
  • the compositions contain a solution of paracetamol in an aqueous solvent combined with a buffer having a pH of 4 to 8, and a frfee radical capturing agent.
  • a water-insoluble inert gas is carefully bubbled through the aqueous solvent to remove oxygen from the medium.
  • Said compositions may also be combined with a centrally or peripherally acting analgesic agent, and are provided as inject able compositions for relieving pain.
  • An object of the invention is to design a direct injection method for the paracetamol and diclofenac sodium. Another object of the invention is to formulate intravenous formulation of the paracetamol and diclofenac sodium in combination. Yet another object of the invention is to prepare water based formulation of intravenous administration of the paracetamol and diclofenac sodium.
  • Present invention is related to intravenous administration of the paracetamol and disclofe ⁇ ac sodium in combination, in this method paracetamol powder and diclofenac sodium are dissolved separately in the aqueous phase and suitable pH is adjusted by acid or base and this solution is directly administrated in the patients body though the direct injection.
  • the subject in the methods described herein can be, e.g., a mammal, e.g., a human, mouse, rat, dog, cat, horse, cow, pig, or non-human primate.
  • the subject is a juvenile human, e.g., a subject less than 7 years of age.
  • pharmaceutically effective amount means that amount of a drug or pharmaceutical agent that will elicit the biological or medical response of a tissue, system, animal or human that is being sought by a researcher or clinician.
  • compositions are preferably suitable for internal use and include an effective amount of a pharmacologically active compound of the invention, alone or in combination, with one or more pharmaceutically acceptable carriers!
  • the compounds are especially useful in that they have very low, if any, toxicity.
  • the method of administration of the paracetamol and diclofenac sodium in the present invention is through the intravenous route through an aqueous vehicle.
  • the paracetamol is dissolved in water for injection.
  • the injection thus prepared also contains adjuvants, buffers isotonic.
  • Adjuvants are pharmacological or immunological agents that modify the effect of other agents (e.g., drugs, vaccines) while having few if any direct effects when given by themselves. In this sense, they are roughly analogous to chemical,
  • Sodium sulfite sodium sulphite
  • ⁇ t is also used as a presser to prevent dried fruit from discoloring, and for preserving meats, and is used in the same way as sodium thiosulfate to convert elemental halides to their respective acids
  • PBS Phosphate buffered saline
  • the buffer helps to maintain a constant pH
  • the osmolarity and ion cone Potassium hydrogen phthalate, often called simply KHP, is a white or colorless, ionic soiid that is the monopotasssum salt of phthalic acid.
  • the hydrogen is slightly acidic, and it is often used as a primary standard for acid-base titrations because it is solid and air-stable, making it easy to weigh accurately. It is, however, slightly hygroscopic and is generally kept in a desiccator before use. It is also used as a primary standard for calibrating pH meters because, besides the properties just mentioned, its pH in solution is very stable.
  • KHP can be used as a buffering agent (in combination with HCI or NaOH depending on which side of pH 4.0 the buffer is to be) but should not be used as a buffer for decarboxylation reactions, as these will degrade the KHP and mop up the conjugation groups
  • Stability of the aqueous solutions mentioned above does not solely depend on the choice of a given earner, ⁇ t also depends on other variables, such as careful adjustment of pH, removal of oxygen dissolved in the carrier and addition of a free radical antagonist or a free radical scavenger.
  • Removal of dissolved oxygen is readily accomplished by bubbling an inert gas and preferably by bubbling nitrogen.
  • the appropriate free radical antagonist is chosen among the derivatives of ascorbic acid, those derivatives bearing at least a thiol functional group and straight chain or . cyclic polyhydric compounds.
  • Preferred ascorbic acid derivatives are D- or L-ascorbic acid, an alkali metal ascorbate, an alkaline earth metal ascorbate or even still an aqueous medium- soluble ascorbic acid ester.
  • Free radical scavengers, bearing a thiol functional group may be an organic compound substituted by one or more thiol functional groups, of the aliphatic series such as cystein, acetylcy stein, thioglycollic acid and salts thereof, thiolactic acid and salts thereof, dithlothr ⁇ ltol, reduced glutathion, thiourea, thioglycerol, methionine and mercaptoethane sulfonic acid,
  • the polyol used as a free radical scavenger is preferably a straight chain or a cyclic, polyhydroxy alcohol such as mannitol, sorbitol, inositol, isosorbide, glycerol, glucose and propylene-glycols.
  • the ascorbic acid derivative currently preferred is sodium ascorbate.
  • Preferred thiol functional group substituted derivatives are cystein, reduced-slate glutathion, N- acetylcystein and mercaptoethane sulfonic acid.
  • free radical scavengers it may appear as convenient to combine several free radical scavengers as far as they are water-soluble and mutually compatible. Especially convenient free radical scavengers are mannitol, glucose, sorbitol or even glycerol. These may be readily combined.
  • Sodium chloride also known as common salt, table salt, or halite is a chemical compound with the formula Sodium chloride is the salt most responsible for the salinity.
  • the gas that is bubbled into the solution to drive out oxygen may be nitrogen or carbon dioxide or still an inert gas. Nitrogen is favoured.
  • lsotonicity of the preparation may be achieved by adding an appropriate quantity of sodium chloride, glucose, Sevulose or postassium chloride, or calcium chloride, or calcium gluconoglucoheptonate, or mixtures thereof.
  • the preferred isotonizing agent is sodium chloride.
  • the buffer used is a buffer compatible with parenteral administration in humans, the pH of which roay be adjusted between 4 and 8.
  • Preferred buffers are based on alkali metal alkaline earth metal acetates or phosphates.
  • a more preferred buffer is sodium acetate/hydrogene phosphate adjusted to the required pH with hydrochloric acid or sodium hydroxide.
  • the concentration of such a buffer may be comprised between 0.1 and 10 mg/ml. The preferred concentration is confined in the range of 0.25 to 5 mg/ml.
  • antioxidants such as glutathion are broken down JFIALAIRC A. et al., J. Pharm. Biomed. Anal., vol. 10, No 6, pp. 457-460 (1992)].
  • the breakdown of reduced giutathion during heat treatment sterilization ranges from 40 to 77% depending on the selected temperature conditions.
  • Addition of complexing agents to aqueous solutions inhibits thermal decomposition of thiol derivatives, such as glutathion, edentate sodium.
  • Liquid pharmaceutical compositions according to the invention are preferably compositions intended for injection.
  • the paracetamol content of the solution may range from 2 mg/ml to 50 mg/ml in case of so calied dilute solutions, i.e. that can be directly infused by intravenous route and from 60 mg/ml to 350 mg/ml where so-called concentrated solution are considered, i.e. either intended for direct injection by intravenous or intramuscular route, or intended to be diluted prior to slow infusion administration.
  • the preferred concentration are comprised between 5 and 20 mg/ml for dilute solutions and between 100 and 250 mg/ml for concentrated solutions or mostly the amount which is pharmaceutically effective amount is used for ihe preparation of the said formulation.
  • compositions according to the invention may further contain another active ingredient that enhances the specific effect of paracetamol.
  • compositions according to the invention diclofenac such as for exampie a diclofenac sodium
  • isotonic may refer to
  • Concentration of the solution usually match those of the human body (isotonic). The process is earned at the different temperatures. The activity increases after the direct administration of the paracetamol and patient gains immediate relief.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne l'administration de paracétamol & sodium de diclofénac par voie intraveineuse dans un véhicule aqueux. On dissout le paracétamol & sodium de diclofénac dans de l'eau aux fins d'injection à l'aide d'éléments passifs assurant une fonction tampon, isotonique, etc. L'opération est conduite à différentes températures. L'activité du paracétamol & sodium de diclofénac augmente après dissolution sous forme aqueuse, et l'on procure ainsi un confort accru au patient.
PCT/IN2008/000754 2008-06-25 2008-11-05 Système de distribution de médicament par voie intraveineuse WO2009157010A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1529DE2008 2008-06-25
IN1529/DEL/2008 2008-06-25

Publications (1)

Publication Number Publication Date
WO2009157010A1 true WO2009157010A1 (fr) 2009-12-30

Family

ID=41444113

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2008/000754 WO2009157010A1 (fr) 2008-06-25 2008-11-05 Système de distribution de médicament par voie intraveineuse

Country Status (1)

Country Link
WO (1) WO2009157010A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170304357A1 (en) * 2016-03-30 2017-10-26 Baylor University Nutraceutical containing an oxygen-enabled composition
US10137146B2 (en) * 2016-03-30 2018-11-27 Baylor University Oxygen-enabled composition
US10369101B2 (en) 2013-03-15 2019-08-06 Latitude Pharmaceuticals Inc. Parenteral diclofenac composition

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6028222A (en) * 1996-08-05 2000-02-22 Scr Pharmatop Stable liquid paracetamol compositions, and method for preparing same
US20060293228A1 (en) * 2005-06-24 2006-12-28 Bhatnagar Rajendra S Therapeutic compositions and methods using transforming growth factor-beta mimics

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6028222A (en) * 1996-08-05 2000-02-22 Scr Pharmatop Stable liquid paracetamol compositions, and method for preparing same
US20060293228A1 (en) * 2005-06-24 2006-12-28 Bhatnagar Rajendra S Therapeutic compositions and methods using transforming growth factor-beta mimics

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10369101B2 (en) 2013-03-15 2019-08-06 Latitude Pharmaceuticals Inc. Parenteral diclofenac composition
US20170304357A1 (en) * 2016-03-30 2017-10-26 Baylor University Nutraceutical containing an oxygen-enabled composition
US9950006B2 (en) * 2016-03-30 2018-04-24 Baylor University Nutraceutical containing an oxygen-enabled composition
US10137146B2 (en) * 2016-03-30 2018-11-27 Baylor University Oxygen-enabled composition

Similar Documents

Publication Publication Date Title
US7404964B2 (en) Injectable compositions for the controlled delivery of pharmacologically active compound
MX2007013583A (es) Metodos y composiciones para tratar el dolor.
TW200302720A (en) Highly concentrated stable meloxicam solutions for needleless injection
JP2010525083A5 (fr)
KR20080016689A (ko) 약물주사가 가능한 새로운 형태의 조성물 및 이러한조성물을 위한 조제방법
KR101777587B1 (ko) 주사가능한 이부프로펜 제제
US20210128507A1 (en) Formulation for use in a method of treatment of pain
KR102656841B1 (ko) 레파뮬린의 주사가능한 약제학적 제형
CA2596031C (fr) Preparations injectables de diclofenac et sels acceptables sur le plan pharmaceutique de celui-ci
JP2012144449A (ja) ルリコナゾールの皮膚浸透性を向上させる配合処方
ES2866981T3 (es) Disolución de levodopa para infusión
WO2009157010A1 (fr) Système de distribution de médicament par voie intraveineuse
KR20120089623A (ko) 정맥내 투여용 이부프로펜을 이용한 환자의 치료
US9211251B2 (en) Injectable preparations of diclofenac and its pharmaceutically acceptable salts
RU2290922C1 (ru) Средство для лечения болезней суставов
ES2432222B1 (es) Composición farmacéutica inyectable de dexketoprofeno y tramadol
PT2262493E (pt) Métodos de tratamento empregando infusão contínua prolongada de belinostat
WO2009150278A1 (fr) Composition pharmaceutique de melphalan
CN101057845B (zh) 草乌甲素干乳剂及其制备方法与应用
RU2578433C1 (ru) Противотуберкулёзная фармацевтическая композиция для парентерального применения в дозировках малого объема
KR20170099911A (ko) 파라세타몰 주사 제제
WO2009157009A1 (fr) Système de distribution de médicament par voie intraveineuse
US20150141518A1 (en) Water-miscible stable solution composition for pharmaceutically active ingredients that are poorly soluble in water and susceptible to chemical degradation
CN102379844A (zh) 一种伊曲康唑异构体注射剂

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08874798

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08874798

Country of ref document: EP

Kind code of ref document: A1